WHAT IS CLAIMED IS:

1. A composition for use as a sustained-release injection comprising deslorelin, the composition comprising microparticles, wherein the microparticles comprise deslorelin and a biodegradable polymer, and a value according to the following Equation 1 is 1 to 10:

[Equation 1]

$C_{max\ 1d\text{-}28d}/C_{max\ 0\text{-}1d}$, and

wherein the microparticles have a value according to the following Equation 2 of 1 to 2:

[Equation 2]

$$\frac{D90-D50}{D50-D10}$$

where,

the composition is to be administered as an injection product to a beagle dog for measuring the blood concentration of deslorelin,

$C_{max\ 1d\text{-}28d}$ is the maximum blood concentration of deslorelin within 1 to 28 days after the injection product has been injected,

$C_{max\ 0\text{-}1d}$ is the maximum blood concentration of deslorelin within 1 day after the injection product has been injected,

D10 is the diameter of the particles corresponding to 10% of the maximum value in the cumulative distribution of particles,

D50 is the diameter of the particles corresponding to 50% of the maximum value in the cumulative distribution of particles, and

D90 is the diameter of the particles corresponding to 90% of the maximum value in the cumulative distribution of particles.

2. The composition of claim 1, wherein the biodegradable polymer is selected from the group consisting of polylactic acid, polylactide, polylactic-co-glycolic acid,

polylactide-co-glycolide (PLGA), polyphosphazines, polyiminocarbonates, polyphosphoesters, polyanhydrides, polyorthoesters, polycaprolactone, polyhydroxyvalate, polyhydroxybutyrate, polyamino acids, and combinations thereof.

3. The composition of claim 2, wherein the biodegradable polymer has a viscosity of 0.1 to 1.0 dl/g.

4. The composition of claim 1, wherein deslorelin and the biodegradable polymer are contained at a weight ratio of 1:4 to 1:10.

5. The composition of claim 1, wherein when the injection product has been administered, the release rate of deslorelin at the target site is adjusted, and the inhibitory effect of testosterone due to deslorelin lasts for 1 month or more.

6. The composition of claim 1, wherein testosterone is maintained at 0.4 ng/ml or less after 10 days have passed since the injection product has been administered.

7. The composition of claim 1, wherein the composition comprises a suspension solvent.

8. A method for preparing a composition for sustained-release injection comprising deslorelin, the method comprising the steps of:

1) preparing a first mixture by mixing deslorelin and a biodegradable polymer;

2) preparing a second mixture by dissolving a surfactant in a solvent;

3) injecting the first mixture and the second mixture into a first microchannel and a second microchannel respectively in which an intersection point is formed, and allowing them

to flow therethrough to produce microparticles at the intersection point, wherein when the first mixture is injected into the first microchannel, after the first mixture is injected under a pressure condition of 700 to 1,500 mbar, the pressure is increased to a first condition of 10 to 30 mbar/min, and when the injection pressure condition reaches 900 to 1,700 mbar, the pressure is increased to a second condition of 2 to 8 mbar/min;

4) collecting the microparticles in a water tank containing the second mixture;

5) removing an organic solvent present in the collected microparticles;

6) washing the organic solvent-removed microparticles with purified water and drying the washed microparticles; and

7) mixing the dried microparticles with a suspension solution, and

a value according to the following Equation 1 is 1 to 10:

[Equation 1]

$C_{max\ 1d\text{-}28d}/C_{max\ 0\text{-}1d}$, and

wherein the microparticles have a value according to the following Equation 2 of 1 to 2:

[Equation 2]

$$\frac{D90-D50}{D50-D10}$$

where,

the composition is to be administered as an injection product to a beagle dog to measure the blood concentration of deslorelin,

$C_{max\ 1d\text{-}28d}$ is the maximum blood concentration of deslorelin within 1 to 28 days after injecting the injection product,

$C_{max\ 0\text{-}1d}$ is the maximum blood concentration of deslorelin within 1 day after injecting the injection product,

D10 is the diameter of the particles corresponding to 10% of the maximum value in the cumulative distribution of particles,

D50 is the diameter of the particles corresponding to 50% of the maximum value in the cumulative distribution of particles, and

D90 is the diameter of the particles corresponding to 90% of the maximum value in the cumulative distribution of particles.

9. The method of claim 8, wherein the second mixture is injected into the second microchannel under a pressure condition that is 2 to 4 times greater than the pressure condition when the first mixture is injected into the first microchannel.

10. The method of claim 8, wherein the step 5) includes the steps of: 5-1) performing primary stirring at a speed of 100 to 300 rpm for 20 to 40 minutes at 15 to 20°C; 5-2) performing secondary stirring at a speed of 100 to 300 rpm for 60 to 120 minutes at 30 to 40 °C; and 5-3) performing tertiary stirring at a speed of 100 to 300 rpm for 4 to 8 hours at 40 to 45°C.

11. Use of a composition in the manufacture of a medicament for chemical castration of a beagle dog,

wherein the medicament is to be administered by injection to the beagle dog,

wherein the composition is formulated as a sustained-release composition, wherein the composition comprises microparticles, wherein the microparticles comprise deslorelin and a biodegradable polymer,

wherein the microparticles have a value according to the following Equation 1 of 1 to 10:

[Equation 1]

$C_{max\ 1d\text{-}28d}/C_{max\ 0\text{-}1d}$, and

wherein the microparticles have a value according to the following Equation 2 of 1 to 2:

[Equation 2]

$$\frac{D90-D50}{D50-D10}$$

where,

$C_{max\ 1d\text{-}28d}$ is the maximum blood concentration of deslorelin within 1 to 28 days after the medicament has been administered,

$C_{max\ 0\text{-}1d}$ is the maximum blood concentration of deslorelin within 1 day after the medicament has been administered,

D10 is the diameter of the particles corresponding to 10% of the maximum value in the cumulative distribution of particles,

D50 is the diameter of the particles corresponding to 50% of the maximum value in the cumulative distribution of particles, and

D90 is the diameter of the particles corresponding to 90% of the maximum value in the cumulative distribution of particles.